Axovant Sciences Ltd (AXON) Receives Sell Rating from Chardan Capital
Axovant Sciences Ltd (NYSE:AXON)‘s stock had its “sell” rating reaffirmed by equities research analysts at Chardan Capital in a research report issued to clients and investors on Friday. They presently have a $3.00 target price on the biotechnology company’s stock. Chardan Capital’s price target points to a potential downside of 62.07% from the company’s current price.
AXON has been the subject of a number of other reports. Jefferies Group LLC set a $40.00 price objective on Axovant Sciences and gave the company a “buy” rating in a research report on Friday, August 25th. Evercore ISI started coverage on Axovant Sciences in a research report on Friday, September 8th. They issued an “outperform” rating and a $30.00 price objective for the company. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $30.00 price objective on shares of Axovant Sciences in a research report on Monday, September 25th. CIBC boosted their price objective on Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, June 14th. Finally, BidaskClub upgraded Axovant Sciences from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Four equities research analysts have rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company’s stock. Axovant Sciences has an average rating of “Hold” and a consensus target price of $14.68.
Shares of Axovant Sciences (AXON) opened at 7.92 on Friday. The firm’s 50-day moving average is $16.23 and its 200-day moving average is $16.23. Axovant Sciences has a one year low of $6.13 and a one year high of $27.98. The stock’s market capitalization is $851.60 million.
Axovant Sciences (NYSE:AXON) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.12). Equities research analysts forecast that Axovant Sciences will post ($2.02) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/10/06/axovant-sciences-ltd-axon-receives-sell-rating-from-chardan-capital.html.
Several institutional investors and hedge funds have recently modified their holdings of AXON. FMR LLC increased its position in shares of Axovant Sciences by 968.5% during the second quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock worth $167,794,000 after purchasing an additional 6,558,462 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in Axovant Sciences in the 2nd quarter valued at $47,854,000. Capital Research Global Investors grew its holdings in Axovant Sciences by 21.8% in the 2nd quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock valued at $80,094,000 after buying an additional 619,226 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in Axovant Sciences by 1,718.3% in the 1st quarter. Point72 Asset Management L.P. now owns 209,100 shares of the biotechnology company’s stock valued at $3,124,000 after buying an additional 197,600 shares in the last quarter. Finally, State Street Corp grew its holdings in Axovant Sciences by 52.8% in the 2nd quarter. State Street Corp now owns 546,920 shares of the biotechnology company’s stock valued at $12,682,000 after buying an additional 188,945 shares in the last quarter.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.